Zhongchao (NASDAQ:ZCMD – Get Free Report) was upgraded by investment analysts at Wall Street Zen from a “strong sell” rating to a “sell” rating in a report released on Saturday, Wall Street Zen reports.
Separately, Weiss Ratings lowered Zhongchao from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 25th. One investment analyst has rated the stock with a Sell rating. According to MarketBeat.com, Zhongchao has an average rating of “Sell”.
Zhongchao Stock Performance
Zhongchao stock opened at $0.91 on Friday. The company’s 50-day moving average price is $1.43 and its 200-day moving average price is $147.68. Zhongchao has a twelve month low of $0.87 and a twelve month high of $1,443.36.
About Zhongchao
Zhongchao Inc. (NASDAQ: ZCMD) is a China-based healthcare services company focused on medical education and patient management. Through its operating subsidiaries, the company provides services intended to support healthcare professionals, patients and pharmaceutical or medical-product companies, with an emphasis on oncology and other chronic disease areas. Zhongchao’s medical education activities have included online and offline educational programs, academic conferences, seminars and other professional training initiatives for physicians and healthcare providers.
Featured Articles
- Five stocks we like better than Zhongchao
- Intuitive Machines’ Business Is Taking Off—Will Its Stock Follow?
- The Next Big Thing May Not Be One Thing: Inside Lazard’s Megatrends ETF
- 3 Power and Grid Stocks That Could Keep Growing Even if AI Spending Slows
- Applied Materials Beats and Raises, But Investors Stay Unconvinced
Receive News & Ratings for Zhongchao Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zhongchao and related companies with MarketBeat.com's FREE daily email newsletter.
